Report Detail

Other Pharmaceutical Excipients Global Market - Forecast to 2025

  • RnM3570744
  • |
  • 12 March, 2020
  • |
  • Global
  • |
  • 648 Pages
  • |
  • IQ4I Research & Consultancy
  • |
  • Other

Pharmaceutical excipients are inactive substances in the drug which helps in modulating solubility, bioavailability, and stability of active substances for formulating final drug dosage forms. The excipients form the major part in any medicinal product and proportion of it when compared to Active Pharmaceutical Ingredient (API) exceeds two to three folds in any pharmaceutical preparations. Hence, various characteristics such as functionality, regulatory status, sources, cost, consistency, bioavailability, physicochemical properties, stability, and pharmacokinetic parameters, etc. play a major role in determining the suitability of a substance as an excipient.
As estimated by IQ4I Research, the pharmaceutical excipients global market is expected to grow at a single digit CAGR from 2018 to 2025 to reach $9,911.2 million by 2025. The pharmaceutical excipients market is segmented by source, products, process, functionality, drug dosage forms and finished products.
Pharmaceutical excipients market by the source is segmented as animal-based, plant-based, mineral-based and synthetic based excipients. Plant-based excipients held the highest revenue in 2018 and it is a fastest growing segment at a high single digit CAGR from 2018 to 2025, due to plant-based excipients are cost-effective, low toxic with the better patient tolerance, bio-compatible and they are easily available. By-products, excipients are segmented into inorganic chemicals, organic chemicals and pharmaceutical water. The organic chemicals segment held the highest revenue in 2018 and it is expected to grow at a single digit CAGR from 2018 to 2025, due to the use of these excipients in majorly all of the pharmaceutical formulations as they offer advantages such as increased efficacy in oral delivery of poorly soluble molecules along with increased compressibility and flowability properties.
Inorganic chemical excipients market by type, are further divided into calcium salts, halites, metallic oxides, silicates, and other inorganic chemicals, among which metallic oxides held a major revenue in 2018 and Calcium salts segment is expected to grow at a high single digit CAGR from 2018 to 2025. Calcium salts are further sub-segmented into calcium phosphate and calcium carbonate, among which calcium phosphate held the highest revenue in 2018 and calcium carbonate segment is expected to grow at a high single digit CAGR from 2018 to 2025. Calcium carbonate is further classified into GCC and PCC, among which PCC held the highest revenue in 2018 and it is expected to grow at a high single digit CAGR from 2018 to 2025. Metallic oxides segment are further segmented into titanium dioxide and Others (Iron Oxide, Magnesium Oxide & Aluminum Hydroxide). Titanium Dioxide held the highest revenue in 2018 and it is expected to grow at a mid single digit CAGR from 2018 to 2025.
Organic chemical excipients market by type is further divided into carbohydrates, petrochemicals, oleochemicals, proteins, and other organic chemicals. Oleochemicals held major revenue in 2018 and it is expected to grow at a high single digit CAGR from 2018 to 2025.
Carbohydrate excipients market by type is further segmented into sugar, starch, and cellulose, among which sugar held the largest revenue in 2018 and expected to grow at a mid single digit CAGR from 2018 to 2025. Sugar segment is further divided into actual sugar, sugar alcohol, and artificial sweeteners, where actual sugar held the largest revenue in 2018 and sugar alcohol segment is expected to grow at a mid single digit CAGR from 2018 to 2025.
Actual sugar segment is further sub-segmented into lactose, sucrose, and dextrose, where lactose held the largest revenue in 2018 and dextrose segment is expected to grow at a mid single digit CAGR from 2018 to 2025. Sugar alcohol segment is further classified into sorbitol, mannitol and other sugar alcohols, where mannitol held the largest revenue in 2018 and it is expected to grow at a high single digit CAGR from 2018 to 2025. The starch segment is further divided into modified starch, dried starch and converted starch, where modified starch held the largest revenue in 2018 and dried starch is expected to grow at a mid single digit CAGR from 2018 to 2025. Cellulose segment is further sub-segmented into cellulose ethers, cellulose esters, croscarmellose sodium, and microcrystalline cellulose, where cellulose ethers held the largest revenue in 2018 and microcrystalline cellulose is expected to grow at a mid single digit CAGR from 2018 to 2025.
Petrochemical excipients market by type is further segmented into glycols, povidones, mineral hydrocarbons, acrylic polymers, and other petrochemical excipients. Glycol held the largest revenue in 2018 and acrylic polymers is expected to grow at a high single digit CAGR from 2018 to 2025. Glycol segment is further segmented into Polyethylene Glycol and Propylene Glycol, where Polyethylene Glycol held the largest revenue in 2018 it is expected to grow at a mid single digit CAGR from 2018 to 2025.
Oleochemicals excipients market by type is further segmented into Fatty Alcohols, Metal stearates, Glycerin, and Other Oleochemical Excipients. Fatty Alcohol held the largest revenue in 2018 and Metal stearates is expected to grow at a high single digit CAGR from 2018 to 2025.
Pharma/USP water excipients market by type is further segment into the water for injections and purified water. Water for injections held the largest revenue in 2018 and it is expected to grow at a mid single digit CAGR from 2018 to 2025. Pharmaceutical excipients market by the process is segmented as granulation and direct compression. Granulation held the largest revenue in 2018 and direct compression is expected to grow at a high single digit CAGR from 2018 to 2025.
Pharmaceutical excipients market by functionality is segmented as preservatives, solvent, binders & adhesives, fillers & diluents, suspending agent, coatings, solubilizer, disintegrant, colorant, flavoring & sweeteners, lubricants & glidants, and others. Binders & Adhesives held the largest revenue in 2018 and it is expected to grow at a high single digit CAGR from 2018 to 2025.
Pharmaceutical excipients market by dosage forms is segmented as solid dosage forms, injectables and semisolid, liquid and gaseous. Solid dosage forms held the largest revenue in 2018 and it is expected to grow at a high single digit CAGR from 2018 to 2025. Some of the factors driving the market are solid dosage forms are cost-effective, solid dosage provides increased physical and chemical stability, controlled-release options, and superior ease of handling.
Pharmaceutical excipients market by finished products is segmented as Prescription drugs and OTC. Prescription drugs held the largest revenue in 2018 and it is expected to grow at a mid single digit CAGR from 2018 to 2025.
Pharmaceutical excipients market by region is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of Europe), Asia-Pacific (China, India, Japan, and Others) and Rest of the world (Brazil, Rest of Latin America and Middle East & others). North America held the highest revenue in 2018, due to increasing demand for functional excipients, implementation of new novelties like nanotechnology, increasing usage of oral solid dosage forms, increasing incidence of chronic disorders, elderly population and favorable reimbursement scenario for drugs. Asia-Pacific is the fastest growing region with a high single digit CAGR from 2018 to 2025, due to increasing excipients outsourcing by companies, low manufacturing, and low labor costs, adopting modern innovations like nanotechnology, advancement in the development of functional excipients, rise in chronic diseases, growing generics market owing to patent cliffs, rising healthcare demand, better infrastructure, lower capital, and overhead costs. Excipients manufacturers in developing countries face major challenges to develop product with quality at an affordable price, due to lower price of excipients and large number of producers, which creates a price sensitive market. Some manufacturers may compromise the quality of product in order to keep prices low and boost sales, while some of the manufacturers having a larger market for their products, can sell their higher volume excipients at a slightly lower price.
Some of the key players contributing at global level for pharmaceutical excipients market growth are Dow DuPont (U.S.), Ashland, Inc. (U.S.), BASF SE (Germany), DFE Pharma (Germany), Evonik Industries AG (Germany), Associated British Foods Plc (U.K.), Merck KGAA (U.S.), Roquette (France), Colorcon (U.S.), and Asahi Kasei (Japan).
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
• North America
o U.S.
o Rest of North America
• Europe
o Germany
o France
o Italy
o Rest of Europe
• Asia-Pacific
o China
o India
o Japan
o Rest of APAC
• Rest of the World (RoW)
o Brazil
o Rest of Latin America
o Middle East and Others


1 EXECUTIVE SUMMARY 34

    2 INTRODUCTION 41

    • 2.1 KEY TAKEAWAYS 41
    • 2.2 SCOPE OF THE REPORT 42
    • 2.3 REPORT DESCRIPTION 42
    • 2.4 MARKETS COVERED 47
    • 2.5 STAKEHOLDERS 49
    • 2.6 RESEARCH METHODOLOGY 49
      • 2.6.1 MARKET SIZE ESTIMATION 51
      • 2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION 53
      • 2.6.3 SECONDARY SOURCES 54
      • 2.6.4 KEY DATA POINTS FROM SECONDARY SOURCES 55
      • 2.6.5 PRIMARY SOURCES 56
      • 2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES 57
      • 2.6.7 ASSUMPTIONS 57

    3 MARKET ANALYSIS 59

    • 3.1 INTRODUCTION 59
    • 3.2 MARKET SEGMENTATION 60
    • 3.3 FACTORS INFLUENCING MARKET 62
      • 3.3.1 DRIVERS AND OPPORTUNITIES 63
        • 3.3.1.1 Growth in generics and biosimilar drugs 63
        • 3.3.1.2 Increasing demand for OSDF excipients 63
        • 3.3.1.3 Increasing demand for multifunctional excipients 64
        • 3.3.1.4 Drug-coated medical devices 65
        • 3.3.1.5 Increased demand for solubility enhancing excipients 66
        • 3.3.1.6 Rising demand for sustained or controlled release formulations 67
        • 3.3.1.7 Novel excipients for biologic drugs 67
        • 3.3.1.8 Increasing prevalence of chronic diseases, rise in the aging population 68
      • 3.3.2 RESTRAINTS AND THREATS 69
        • 3.3.2.1 Adverse reactions of excipients 69
        • 3.3.2.2 Contamination in formulations 70
        • 3.3.2.3 High market fragmentation with low-profit margins 71
        • 3.3.2.4 Demand for safe and quality excipients by regulatory authorities 71
    • 3.4 REGULATORY AFFAIRS 72
      • 3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION 72
        • 3.4.1.1 ISO 9001: 2015 quality management system 72
      • 3.4.2 INTERNATIONAL PHARMACEUTICAL EXCIPIENTS COUNCIL (IPEC FEDERATION) 73
      • 3.4.3 PHARMACEUTICAL QUALITY GROUP (PQG) 73
      • 3.4.4 U.S. 73
      • 3.4.5 EUROPE 75
      • 3.4.6 JAPAN 75
      • 3.4.7 CHINA 76
      • 3.4.8 INDIA 76
      • 3.4.9 REST OF THE WORLD 77
    • 3.5 PORTER’S FIVE FORCE ANALYSIS 78
      • 3.5.1 THREAT OF NEW ENTRANTS 79
      • 3.5.2 THREAT OF SUBSTITUTES 79
      • 3.5.3 BARGAINING POWER OF SUPPLIERS 80
      • 3.5.4 BARGAINING POWER OF BUYERS 80
      • 3.5.5 COMPETITIVE RIVALRY 81
    • 3.6 SUPPLY CHAIN ANALYSIS 82
    • 3.7 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 85
      • 3.7.1 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET SHARE ANALYSIS 85
    • 3.8 NOVEL EXCIPIENTS 89
    • 3.9 MOLECULE TYPE 90
    • 3.10 DRUG MASTER FILING (DMF) 94
    • 3.11 EXCIPIENTS BY MOLECULE TYPE 95
    • 3.12 EXCIPIENTS PRICING 96
    • 3.13 GLOBAL PHARMACEUTICAL EXCIPIENTS PRODUCTION VOLUME 99
    • 3.14 EXCIPIENTS USED IN GLOBAL TOP 100 SELLING DRUGS BY REVENUE 101
    • 3.15 EXCIPIENT MANUFACTURER’S REVENUE, PRODUCT, FUNCTIONALITY AND DOSAGE FORMS 148

    4 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET, BY SOURCE 156

    • 4.1 INTRODUCTION 156
    • 4.2 ANIMAL BASED EXCIPIENTS 159
    • 4.3 PLANT BASED EXCIPIENTS 162
    • 4.4 MINERAL BASED EXCIPIENTS 165
    • 4.5 SYNTHETIC BASED EXCIPIENTS 168

    5 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET, BY PRODUCT 171

    • 5.1 INTRODUCTION 171
    • 5.2 INORGANIC CHEMICALS 175
      • 5.2.1 CALCIUM SALTS 181
        • 5.2.1.1 Calcium phosphate 186
        • 5.2.1.2 Calcium carbonate 188
        • 5.2.1.2.1 GCC 192
        • 5.2.1.2.2 PCC 194
        • 5.2.1.3 OTHER CALCIUM SALT 196
      • 5.2.2 HALITES 198
      • 5.2.3 METALLIC OXIDES 201
        • 5.2.3.1 Titanium dioxide 206
        • 5.2.3.2 Other metallic oxides 207
      • 5.2.4 SILICATES 209
      • 5.2.5 OTHER INORGANIC CHEMICALS 213
    • 5.3 ORGANIC CHEMICALS 216
      • 5.3.1 CARBOHYDRATES 222
        • 5.3.1.1 Sugar 228
        • 5.3.1.1.1 Actual sugar 231
        • 5.3.1.1.2 Sugar alcohol 240
        • 5.3.1.1.3 Artificial sweeteners 249
        • 5.3.1.2 Starch 251
        • 5.3.1.2.1 Modified starch 255
        • 5.3.1.2.2 Dried starch 258
        • 5.3.1.2.3 Converted starch 259
        • 5.3.1.3 Cellulose 261
        • 5.3.1.3.1 Cellulose ethers 265
        • 5.3.1.3.2 Cellulose esters 267
        • 5.3.1.3.3 Croscarmellose sodium 269
        • 5.3.1.3.4 Microcrystalline cellulose 271
        • 5.3.2 PETROCHEMICALS 273
          • 5.3.2.1 Glycol 278
          • 5.3.2.1.1 Polyethylene glycol 280
          • 5.3.2.1.2 Propylene glycol 282
          • 5.3.2.2 Povidones 284
          • 5.3.2.3 Mineral hydrocarbons 286
          • 5.3.2.3.1 Petrolatum 287
          • 5.3.2.3.2 Mineral waxes 287
          • 5.3.2.3.3 Mineral oils 287
          • 5.3.2.4 Acrylic polymers 288
          • 5.3.2.5 Other petrochemicals 290
        • 5.3.3 OLEOCHEMICALS 292
          • 5.3.3.1 Fatty alcohols 297
          • 5.3.3.2 Metal stearates 299
          • 5.3.3.3 Glycerin 301
          • 5.3.3.4 Other oleochemicals 303
        • 5.3.4 PROTEINS 305
        • 5.3.5 OTHER ORGANIC CHEMICALS 308
      • 5.4 PHARMA/USP WATER 311
        • 5.4.1 WATER FOR INJECTION 316
        • 5.4.2 PURIFIED WATER 319

      6 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET, BY MANUFACTURING PROCESS 322

      • 6.1 INTRODUCTION 322
      • 6.2 GRANULATION 325
      • 6.3 DIRECT COMPRESSION 328

      7 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET, BY FUNCTIONALITY 331

      • 7.1 INTRODUCTION 331
      • 7.2 PRESERVATIVES 334
      • 7.3 SOLVENT 337
      • 7.4 BINDERS & ADHESIVES 339
      • 7.5 FILLERS & DILUENTS 342
      • 7.6 SUSPENDING AGENT 345
      • 7.7 COATINGS 348
      • 7.8 SOLUBILIZERS 351
      • 7.9 DISINTEGRANT 354
      • 7.10 COLORANT, FLAVOURING & SWEETENERS 357
      • 7.11 LUBRICANTS & GLIDANTS 360
      • 7.12 OTHERS 363

      8 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET, BY DOSAGE FORMS 368

      • 8.1 INTRODUCTION 368
      • 8.2 SOLID DOSAGE FORMS 371
      • 8.3 INJECTABLES 374
      • 8.4 SEMISOLID, LIQUID AND GASEOUS 377

      9 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET, BY FINISHED PRODUCTS 380

      • 9.1 INTRODUCTION 380
      • 9.2 PRESCRIPTION DRUGS 383
      • 9.3 OVER-THE-COUNTER (OTC) DRUGS 386

      10 REGIONAL ANALYSIS 389

      • 10.1 INTRODUCTION 389
      • 10.2 NORTH AMERICA 394
        • 10.2.1 U.S. 422
        • 10.2.2 REST OF NORTH AMERICA 428
      • 10.3 EUROPE 433
        • 10.3.1 GERMANY 460
        • 10.3.2 FRANCE 464
        • 10.3.3 ITALY 468
        • 10.3.4 REST OF EUROPE 472
      • 10.4 APAC 476
        • 10.4.1 CHINA 503
        • 10.4.2 INDIA 507
        • 10.4.3 JAPAN 512
        • 10.4.4 REST OF APAC 516
      • 10.5 ROW 520
        • 10.5.1 BRAZIL 547
        • 10.5.2 REST OF LATAM 550
        • 10.5.3 MIDDLE EAST & OTHERS 553

      11 COMPETITIVE LANDSCAPE 557

      • 11.1 INTRODUCTION 557
      • 11.2 NEW PRODUCT LAUNCHES 558
      • 11.3 ACQUISITION 561
      • 11.4 AGREEMENTS, COLLABORATION & JOINT VENTURES 562

      12 MAJOR COMPANIES 565

      • 12.1 ASAHI KASEI 565
        • 12.1.1 OVERVIEW 565
        • 12.1.2 FINANCIALS 566
        • 12.1.3 PRODUCT PORTFOLIO 569
        • 12.1.4 KEY DEVELOPMENTS 569
        • 12.1.5 BUSINESS STRATEGY 569
        • 12.1.6 SWOT ANALYSIS 570
      • 12.2 ASHLAND, INC 571
        • 12.2.1 OVERVIEW 571
        • 12.2.2 FINANCIALS 572
        • 12.2.3 PRODUCT PORTFOLIO 575
        • 12.2.4 KEY DEVELOPMENTS 577
        • 12.2.5 BUSINESS STRATEGY 578
        • 12.2.6 SWOT ANALYSIS 579
      • 12.3 ASSOCIATED BRITISH FOODS PLC (SPI PHARMA) 580
        • 12.3.1 OVERVIEW 580
        • 12.3.2 FINANCIALS 581
        • 12.3.3 PRODUCT PORTFOLIO 584
        • 12.3.4 KEY DEVELOPMENTS 585
        • 12.3.5 BUSINESS STRATEGY 585
        • 12.3.6 SWOT ANALYSIS 586
      • 12.4 AVANTOR INC 587
        • 12.4.1 OVERVIEW 587
        • 12.4.2 FINANCIALS 587
        • 12.4.3 PRODUCT PORTFOLIO 588
        • 12.4.4 KEY DEVELOPMENTS 588
        • 12.4.5 BUSINESS STRATEGY 589
        • 12.4.6 SWOT ANALYSIS 590
      • 12.5 BASF SE 591
        • 12.5.1 OVERVIEW 591
        • 12.5.2 FINANCIALS 592
        • 12.5.3 PRODUCT PORTFOLIO 595
        • 12.5.4 KEY DEVELOPMENTS 596
        • 12.5.5 BUSINESS STRATEGY 597
        • 12.5.6 SWOT ANALYSIS 598
      • 12.6 COLORCON, INC. 599
        • 12.6.1 OVERVIEW 599
        • 12.6.2 FINANCIALS 599
        • 12.6.3 PRODUCT PORTFOLIO 600
        • 12.6.4 KEY DEVELOPMENTS 600
        • 12.6.5 BUSINESS STRATEGY 601
        • 12.6.6 SWOT ANALYSIS 602
      • 12.7 CRODA INTERNATIONAL PLC 603
        • 12.7.1 OVERVIEW 603
        • 12.7.2 FINANCIALS 604
        • 12.7.3 PRODUCT PORTFOLIO 607
        • 12.7.4 KEY DEVELOPMENTS 607
        • 12.7.5 BUSINESS STRATEGY 609
        • 12.7.6 SWOT ANALYSIS 610
      • 12.8 DFE PHARMA 611
        • 12.8.1 OVERVIEW 611
        • 12.8.2 FINANCIALS 611
        • 12.8.3 PRODUCT PORTFOLIO 612
        • 12.8.4 KEY DEVELOPMENTS 613
        • 12.8.5 BUSINESS STRATEGY 614
        • 12.8.6 SWOT ANALYSIS 615
      • 12.9 DOW DUPONT INC. 616
        • 12.9.1 OVERVIEW 616
        • 12.9.2 FINANCIALS 617
        • 12.9.3 PRODUCT PORTFOLIO 620
        • 12.9.4 KEY DEVELOPMENTS 621
        • 12.9.5 BUSINESS STRATEGY 621
        • 12.9.6 SWOT ANALYSIS 622
      • 12.10 EVONIK INDUSTRIES AG 623
        • 12.10.1 OVERVIEW 623
        • 12.10.2 FINANCIALS 624
        • 12.10.3 PRODUCT PORTFOLIO 627
        • 12.10.4 KEY DEVELOPMENTS 627
        • 12.10.5 BUSINESS STRATEGY 628
        • 12.10.6 SWOT ANALYSIS 629
      • 12.11 LUBRIZOL CORPORATION 630
        • 12.11.1 OVERVIEW 630
        • 12.11.2 FINANCIALS 630
        • 12.11.3 PRODUCT PORTFOLIO 631
        • 12.11.4 KEY DEVELOPMENTS 632
        • 12.11.5 BUSINESS STRATEGY 633
        • 12.11.6 SWOT ANALYSIS 634
      • 12.12 MERCK KGAA 635
        • 12.12.1 OVERVIEW 635
        • 12.12.2 FINANCIALS 636
        • 12.12.3 PRODUCT PORTFOLIO 639
        • 12.12.4 KEY DEVELOPMENTS 640
        • 12.12.5 BUSINESS STRATEGY 641
        • 12.12.6 SWOT ANALYSIS 642
      • 12.13 ROQUETTE FRÈRES S.A. 643
        • 12.13.1 OVERVIEW 643
        • 12.13.2 FINANCIALS 643
        • 12.13.3 PRODUCT PORTFOLIO 644
        • 12.13.4 KEY DEVELOPMENTS 645
        • 12.13.5 BUSINESS STRATEGY 646

    Summary:
    Get latest Market Research Reports on Pharmaceutical Excipients . Industry analysis & Market Report on Pharmaceutical Excipients is a syndicated market report, published as Pharmaceutical Excipients Global Market - Forecast to 2025. It is complete Research Study and Industry Analysis of Pharmaceutical Excipients market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $4,950.00
    $6,750.00
    $9,000.00
    3,900.60
    5,319.00
    7,092.00
    4,554.00
    6,210.00
    8,280.00
    770,220.00
    1,050,300.00
    1,400,400.00
    412,731.00
    562,815.00
    750,420.00
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report